Prescribing overview
Intravenous chemotherapy for canine lymphoma.
Requires oncology planning, toxicity surveillance and cytotoxic-drug handling. Tanovea-CA1 is the former conditional-approval name.
Key prescribing checks
- Review the full product-specific safety section and the patient’s complete treatment plan.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
US veterinary product labelLymphoma
Patient and indication restrictions apply.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Intracellular metabolites inhibit DNA synthesis and promote cell death.
Absorption, distribution, metabolism and elimination
Plasma drug clears rapidly; active intracellular metabolites persist longer.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Tanovea
US Powder for IV infusion label.
Contraindications · when not to use
- Do not use with pulmonary fibrosis/predisposing chronic lung disease, in West Highland White Terriers, or breeding, pregnant or lactating dogs.
Precautions & monitoring
- Other terriers warrant caution. Extravasation may injure tissue.
Selected safety information; not a complete interaction assessment.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
GI illness, weight loss, neutropenia and skin/ear disease occur; pulmonary fibrosis can be fatal.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
Select a regimen from the current exact-product label with the prescribing veterinarian; no calculator regimen is supplied for this entry.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Tanovea
US Powder for IV infusion label.
- Combination chemotherapy and concomitant-drug metabolic effects are unestablished.
Monitoring
Check blood counts, respiratory status, skin/ears, appetite and weight.
Client counseling
Urgently report breathing changes. Follow the client sheet’s five-day excreta precautions; pregnant/nursing people must not handle the drug.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Refrigerate intact vials; use chemotherapy PPE and exact reconstitution/infusion expiry instructions.
Brands, formulations & ingredient identity
Active ingredients
Rabacfosadine
Other searchable names: Tanovea · Tanovea-CA1
This reference covers the named US product and route; other formulations need separate verification.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Tanovea
- Formulation
- Powder for IV infusion
- Label / product scope
- Dogs
US labeled presentation; verify the current package.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →